Weight-loss drugs are already dropping in price; could they go even lower?

The price of weight loss drugs is falling, making them more accessible to consumers, and the price could get driven even lower.
Highly sought-after drugs like Wegovy and Zepbound both retail at roughly $1,000 each and have been difficult for people without insurance to obtain.
Despite the price drops, the drugs remain costly. Novo Nordisk cut the price of Wegovy by 23 percent for cash payments from $650 to $499 for uninsured patients or people without coverage. The drug's list price of $1,349 has remained unchanged.
Meanwhile, Eli Lilly reduced Zepbound's starter dose to $349 and higher doses to $499 after launching a self-pay program called Lilly Direct. The new doses require patients to manually draw medication from a vial with a syringe.
In prior years, people would pay about $1,500 a month for the drugs, but in recent months have been able to obtain the doses for roughly $400 to $500, according to NBC News.
A May 2024 survey from the health policy group KFF found that half of U.S. adults say it's difficult to afford the medication.
Pressure from Congress and increased competition are some of the factors that led the drugmakers to reduce the cost. This has led to patients paying less out of pocket because they can afford the cheaper prices or their insurance now covers the drugs. More insurance plans have allowed for the drugs because they have been proven to treat heart disease risk and obstructive sleep apnea.
This month, a study published in the New England Journal of Medicine found Zepbound outperformed Wegovy in a head-to-head clinical trial.
Dr David Rind, a primary care physician and the chief medical officer for the Institute for Clinical and Economic Review, told NBC News: 'You're talking $6,000 a year, and that is still probably more than insurers are paying right now.'
He continued: 'If insurance is relying on the fact that not covering it will allow people to buy it out of pocket, as a primary care doctor, I have a lot of concerns about that...For all my complaining about the price, these are drugs that we should want to give to lots of people, but it's been really hard to see how we can afford them.'
But Rind said not to expect dramatic price drops in the foreseeable future. He said those cuts are likely to come when other weight-loss drugs being developed are approved, which could take several years.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

CNBC

2 hours ago

• CNBC

CNBC Daily Open: Trump followed up on his threat to strike Iran — will this help or harm his credibility?

The United States conducted airstrikes on three of Iran's nuclear sites on Saturday, entering Israel's war against Tehran. The timing was unexpected. On Thursday, U.S. President Donald Trump said he was still considering U.S. involvement and would arrive at a decision "within the next two weeks." Financial and political analysts had largely taken that phrase as code word for inaction. "There is also skepticism that the 'two-week' timetable is a too familiar saying used by the President to delay making any major decision," wrote Jay Woods, chief global strategist at Freedom Capital Markets. Indeed, Trump has commonly neglected to follow up after giving a "two week" timeframe on major actions, according to NBC News. And who can forget the TACO trade? It's an acronym that stands for "Trump Always Chickens Out" — which describes a pattern of the U.S. president threatening heavy tariffs, weighing down markets, but pausing or reducing their severity later on, helping stocks to rebound. "Trump has to bury the TACO before the TACO buries him ... he's been forced to stand down on many occasion, and that has cost him a lot of credibility," said David WOO, CEO of David Woo Unbound. And so Trump followed up on his threat, and ahead of the proposed two-week timeline. "There will be either peace, or there will be tragedy for Iran far greater than we have witnessed over the last eight days," Trump said on Saturday evening. But given Trump's criticism of U.S. getting involved in wars under other presidents, does America bombing Iran add to his credibility, or erode it further? The U.S. strikes Iran U.S. President Donald Trump on Saturday said the United States had attacked Iranian nuclear sites, pushing America into Israel's war with its longtime rival. Secretary of Defense Pete Hegseth said Sunday that "Iran's nuclear ambitions have been obliterated," a sentiment echoed by Trump, who stressed that "Obliteration is an accurate term." The decision to attack Iran engages the American military in active warfare in the Middle East — something Trump had vowed to avoid. Iran calls attacks 'outrageous'Iran's Foreign Minister Abbas Araghchi on Sunday said Tehran reserves all options to defend its sovereignty and people after the "outrageous" U.S. attacks on three of its major nuclear enrichment facilities. Iranian state-owned media, meanwhile, reported that Iran's parliament backed closing the Strait of Hormuz, citing a senior lawmaker. The U.S. on Sunday called on China to prevent Iran from doing so. Investors assess U.S. attacksU.S. futures slid Sunday evening stateside as investors reacted to Washington's strikes on Iran. Futures tied to the S&P 500 lost 0.17%, Dow Jones Industrial Average futures fell 0.24% and Nasdaq 100 futures dropped 0.21%. On Monday, Asia-Pacific markets mostly fell at 1:45 p.m. Singapore time. Japan's Nikkei 225 slipped 0.15% and South Korea's Kospi Index retreated 0.3%. However, Hong Kong's Hang Seng Index bucked the trend to climb 0.29%. Oil prices pare gainsU.S. crude oil were up 1.1% to $74.65 per barrel, while global benchmark Brent climbed 1.12% to $77.88 per barrel early afternoon Singapore time. The commodity pared gains from earlier in the day, when prices jumped more than 2% in oil's first trading session after Saturday's events. That said, multiple analysts raised the prospect of oil hitting $100 per barrel, especially if exports through the Strait of Hormuz are affected. [PRO] Eyes on inflation reading Where markets go this week will depend on whether the conflict in the Middle East escalates after the U.S.' involvement. Investors should also keep an eye on economic data. May's personal consumption expenditures price index, the Federal Reserve's preferred gauge of inflation, comes out Friday, and will tell if tariffs are starting to heat up inflation. Why global markets are brushing off U.S. strikes on Iran The U.S. joining the war between Israel and Iran might seem like a geopolitical flash point that would send markets tumbling. Instead, investors are largely shrugging off the escalation, with many strategists believing the conflict to be contained — and even bullish for some risk assets. "The markets view the attack on Iran as a relief with the nuclear threat now gone for the region," said Dan Ives, managing director at Wedbush, adding that he sees minimal risks of the Iran-Israel conflict spreading to the rest of the region and consequently more "isolated." Furthermore, rhetoric around the idea of shutting down the Hormuz waterway has been recurring from Iran, but it has never been acted upon, with experts highlighting that it is improbable.

Yahoo

2 hours ago

• Yahoo

Lilly To Acquire Verve For One-Time Cardiovascular Treatments

Verve Therapeutics, Inc. (NASDAQ:VERV) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Eli Lilly and Company will buy Verve Therapeutics, Inc. (NASDAQ:VERV) for up to $1.3 billion. A woman in a lab coat examining a syringe of gene editing medicine in a laboratory setting. Depending on future milestones, Lilly will pay $10.50 per share in cash, or roughly $1.0 billion, plus a contingent value right of up to $3.00 per share. The purchase is anticipated to be completed in Q3 2025 and represents a 113% premium over Verve Therapeutics, Inc. (NASDAQ:VERV)'s 30-day average share price as of June 16, 2025. Single-dose gene-editing therapies for atherosclerotic cardiovascular disease are being developed by Verve Therapeutics, Inc. (NASDAQ:VERV), including their flagship program VERVE-102, which targets PCSK9. The medication, which is currently in Phase 1b and has been granted FDA Fast Track designation, has the potential to transform care for patients suffering from heterozygous familial hypercholesterolemia and early coronary artery disease. According to Lilly, Verve Therapeutics, Inc. (NASDAQ:VERV)'s platform strengthens its cardiometabolic pipeline. Sekar Kathiresan, CEO of Verve, stressed the company's goal of moving from chronic to one-time care. Insiders of the firm who own 17.8% of the company have decided to tender. While we acknowledge the potential of VERV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Sign in to access your portfolio

CNBC

7 hours ago

• CNBC

CNBC Daily Open: Have Trump's strikes on Iran bolstered or eroded his credibility?

United States on Saturday conducted air strikes on three of Iran's nuclear sites, entering Israel's war against Tehran. The timing was unexpected. On Thursday, U.S. President Donald Trump said he was still considering U.S. involvement and would arrive at a decision "within the next two weeks." Financial and political analysts had largely taken that phrase as code word for inaction. "There is also skepticism that the 'two-week' timetable is a too familiar saying used by the President to delay making any major decision," wrote Jay Woods, chief global strategist at Freedom Capital Markets. Indeed, Trump has commonly neglected to follow up after giving a "two week" timeframe on major actions, according to NBC News. And who can forget the TACO trade? It's an acronym that stands for "Trump Always Chickens Out" — which describes a pattern of the U.S. president threatening heavy tariffs, weighing down markets, but pausing or reducing their severity later on, helping stocks to rebound. "Trump has to bury the TACO before the TACO buries him ... he's been forced to stand down on many occasion, and that has cost him a lot of credibility," said David WOO, CEO of David Woo Unbound. And so Trump followed up on his threat, and ahead of the proposed two-week timeline. "There will be either peace, or there will be tragedy for Iran far greater than we have witnessed over the last eight days," Trump said on Saturday evening. But given Trump's criticism of U.S. getting involved in wars under other presidents, does America bombing Iran add to his credibility, or erode it further? The U.S. strikes Iran U.S. President Donald Trump on Saturday said the United States had attacked Iranian nuclear sites, pushing America into Israel's war with its longtime rival. Secretary of Defense Pete Hegseth said Sunday that "Iran's nuclear ambitions have been obliterated." The decision to attack Iran engages the American military in active warfare in the Middle East — something Trump had vowed to avoid. Iran calls attacks 'outrageous'Iran's Foreign Minister Abbas Araghchi on Sunday said Tehran reserves all options to defend its sovereignty and people after the "outrageous" U.S. attacks on three of its major nuclear enrichment facilities. Iranian state-owned media, meanwhile, reported that Iran's parliament backed closing the Strait of Hormuz, citing a senior lawmaker. The U.S. on Sunday called on China to prevent Iran from doing so. Stock futures in U.S. retreatU.S. futures slid Sunday evening stateside as investors reacted to Washington's strikes on Iran. On Friday, U.S. markets mostly fell. The S&P 500 lost 0.22%, its third consecutive losing session, while the Nasdaq Composite retreated 0.51%. But the Dow Jones Industrial Average eked out a 0.08% gain. The pan-European Stoxx 600 index ticked up 0.13%, but ended the week 1.5% lower. Oil jumps but bitcoin slumpsOil prices jumped Sunday evening in the U.S., its first trading session after Saturday's strikes. U.S. crude oil rose $1.76, or 2.38%, to $75.60 per barrel, while global benchmark Brent was up $1.80, or 2.34%, to $78.81 per barrel. Meanwhile, bitcoin prices briefly dipped below the $99,000 mark Sunday, its lowest level in more than a month, before paring losses. It's now trading around $100,940, down 1.5%. [PRO] Eyes on inflation reading Where markets go this week will depend on whether the conflict in the Middle East escalates after the U.S.' involvement. Investors should also keep an eye on economic data. May's personal consumptions expenditure price index, the Federal Reserve's preferred gauge of inflation, comes out Friday, and will tell if tariffs are starting to heat up inflation. How regime change in Iran could affect global oil prices Senior Israeli officials said this week that their military campaign against Iran could trigger the fall of the regime, an event that would have enormous implications for the global oil market. There are no signs that the regime in Iran is on the verge of collapse, said Scott Modell, CEO of the consulting firm Rapidan Energy Grop. But further political destabilization in Iran "could lead to significantly higher oil prices sustained over extended periods," said Natasha Kaneva, head of global commodities research at JPMorgan, in a note to clients this week. There have been eight cases of regime change in major oil-producing countries since 1979, according to JPMorgan. Oil prices spiked 76% on average at their peak in the wake of these changes, before pulling back to stabilize at a price about 30% higher compared to pre-crisis levels, according to the bank.